200
Participants
Start Date
December 1, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
EQUITY GI
"1. Ensuring appropriate biomarker testing and evidence-based care: Biomarker testing can also help choose treatment. Additionally, a tumor board will be conducted periodically to provide treatment recommendations to the treating physician. Participant will receive standard-of-care treatment if they enroll in this study. Participant will not receive any experimental treatment.~2. Assistance with clinical trial enrollment. The study team will help enroll in a clinical trial appropriate for the condition.~3. Health literacy: The study team will provide information relevant to your diagnosis to enrich your understanding of your condition and treatment. Investigator will provide questionnaires to assess your understanding before and after you have been provided with educational/informational material appropriate for your diagnosis."
RECRUITING
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
Case Comprehensive Cancer Center
OTHER